167 related articles for article (PubMed ID: 34505336)
21. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib.
Ding PN; Becker T; Bray V; Chua W; Ma Y; Xu B; Lynch D; de Souza P; Roberts T
Thorac Cancer; 2019 Oct; 10(10):1879-1884. PubMed ID: 31414729
[TBL] [Abstract][Full Text] [Related]
22. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
23. Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S.
Fanjat Y; Barazzutti H; Di Mauro I; Tabary-Martin L; Duranton-Tanneur V; Gimet S; Bérard H; Pedeutour F
Cancer Genet; 2021 Aug; 256-257():158-161. PubMed ID: 34157597
[TBL] [Abstract][Full Text] [Related]
24. Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
Xie Z; Gu Y; Xie X; Lin X; Ouyang M; Qin Y; Zhang J; Lizaso A; Chen S; Zhou C
Clin Lung Cancer; 2021 May; 22(3):e390-e394. PubMed ID: 32693944
[No Abstract] [Full Text] [Related]
25. ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report.
Chuang X; Chen Y; Yu P; Qiu X; Wang J; Qu X; Teng Y; Liu Y; Jin B
Thorac Cancer; 2018 Nov; 9(11):1513-1518. PubMed ID: 30144282
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
28. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.
Chiang CL; Yeh YC; Chou TY; Chiu CH
J Formos Med Assoc; 2020 Sep; 119(9):1439-1441. PubMed ID: 32173232
[No Abstract] [Full Text] [Related]
29. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
Yang Z; Yang J; Chen Y; Shao YW; Wang X
Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
[TBL] [Abstract][Full Text] [Related]
30. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Bordi P; Del Re M; Minari R; Rofi E; Buti S; Restante G; Squadrilli A; Crucitta S; Casartelli C; Gnetti L; Azzoni C; Bottarelli L; Petrini I; Cosenza A; Ferri L; Rapacchi E; Danesi R; Tiseo M
Lung Cancer; 2019 May; 131():78-85. PubMed ID: 31027702
[TBL] [Abstract][Full Text] [Related]
31. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
[TBL] [Abstract][Full Text] [Related]
32. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.
Takahashi S; Noro R; Seike M; Zeng C; Matsumoto M; Yoshikawa A; Nakamichi S; Sugano T; Hirao M; Matsuda K; Hamada M; Gemma A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924522
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
Joo JW; Hong MH; Shim HS
Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
[TBL] [Abstract][Full Text] [Related]
34. EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
Copia Sperandio R; Luiza Teixeira Tostes F; Vidal Campregher P; Ribeiro Paes V; Moura F; Schvartsman G
Lung Cancer; 2022 Apr; 166():94-97. PubMed ID: 35245845
[TBL] [Abstract][Full Text] [Related]
35. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
36. A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay.
Menon R; Müller J; Schneider P; Lakis S; Thress K; Wolf J; Heukamp L; Heuckmann JM; Griesinger F
J Thorac Oncol; 2016 Sep; 11(9):e105-7. PubMed ID: 27086175
[No Abstract] [Full Text] [Related]
37. Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.
Lu H; Dowell J
In Vivo; 2020; 34(1):315-319. PubMed ID: 31882494
[TBL] [Abstract][Full Text] [Related]
38. Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.
Chen L; Davelaar J; Gaddam S; Kosari K; Nissen N; Chaux G; Lee C; Vail E; Hendifar A; Gong J; Reckamp K; Osipov A
J Natl Compr Canc Netw; 2022 Nov; 21(1):6-11. PubMed ID: 36395704
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
Xing L; Pan Y; Shi Y; Shu Y; Feng J; Li W; Cao L; Wang L; Gu W; Song Y; Xing P; Liu Y; Gao W; Cui J; Hu N; Li R; Bao H; Shao Y; Yu J
Clin Cancer Res; 2020 Dec; 26(23):6168-6175. PubMed ID: 32817079
[TBL] [Abstract][Full Text] [Related]
40. Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
Wang J; Chen J
BMC Cancer; 2019 Feb; 19(1):131. PubMed ID: 30736738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
